

INTERMITTENT CYCLIC THERAPY WITH ETIDRONATE PREVENTS CORTICOSTEROID-INDUCED BONE LOSS: THREE [...]

XI Zjazd Polskiego Towarzystwa Osteoartrologii i Polskiej Fundacji Osteoporozy
V Krakowskie Sympozjum Osteoporozy
Kraków 27-29.09.2001

Streszczenia:

wersja polska

Materiały kongresowe: STRESZCZENIA, s130-131.

Druk: Drukarnia Skinder, ISBN – 83-904008-5-5

wersja angielska

Osteoporosis International 2001; vol. 12 (Suppl 1), s31.

P048

INTERMITTENT CYCLIC THERAPY WITH ETIDRONATE PREVENTS CORTICOSTEROID-INDUCED BONE LOSS: THREE YEARS OF FOLLOW-UP (PRZERYWANA, CYKLICZNA TERAPIA ETYDRONIANEM ZAPOBIEGA POSTEROIDOWEJ UTRACIE MASY KOSTNEJ – TRZY LATA OBSERWACJI)

Wojciech P. Olszynski¹, Rolf J. Sebaldt², Jonathan D. Adachi², Annie Petrie², Greg Stephenson³, Charles H. Goldsmith².

1University of Saskatchewan,

2McMaster University,

3Procter & Gamble Pharmaceuticals. Suite 103 – 39 Twenty-Third Street East, Saskatoon, Saskatchewan CANADA S7K 0H6

We determined the effectiveness of 3 years of intermittent cyclic therapy with etidronate (ICT-E) in preventing bone loss

in patients receiving corticosteroid (CS) therapy. We analyzed the clinical records of patients seen at our tertiary care Osteoporosis Centre, whose data are routinely collected prospectively into a standardized database.

Patients treated with CS for at least 3 years were selected for the study group if they were concomitantly treated with ICT-E. A comparison (Comp) group was selected of CS-treated patients who were treated with no bone-active therapy other than calcium and vitamin D. Patients were excluded if they had known causes of secondary osteoporosis, were treated with any other bone-active therapy within the preceding 2 years or did not have a bone mineral density (BMD) determination at baseline and after approximately 1, 2 and 3 years of follow-up.

There were 24 and 37 patients in the ICT-E and Comp groups. The groups were comparable in baseline age, 60;16 vs 55;14 yrs (mean;SD), and mean CS dose during the study period (prednisone 13 vs 10 mg/day). The groups differed in prior duration of CS therapy, respectively 11;11 vs 3;4 yrs. In the ICT-E group, LS-BMD increased significantly relative to baseline at each yearly follow-up time point, by +3.8;5.8%, $p=0.006$ (1 yr), +5.0;8.0%, $p=0.006$ (2 yr) and +5.2;9.8%, $p=0.01$ (3 yr). In the Comp group, LS-BMD changed by -3.6;6.4% ($p=0.0005$), -3.2;7.8% ($p=0.007$) and -1.3;9.1% ($p=0.3$), respectively. The differences in these percent changes between the two groups were significant at each time point, $p=0.00003$ (1 yr), $p=0.0002$ (2 yr) and $p=0.01$ (3 yr). These data suggest that ICT-E is an effective treatment for CS-induced osteoporosis over a period of 3 years of continuing CS therapy. These findings extend the conclusions of controlled trials conducted over shorter periods of CS therapy.